font size:

 

 

 

ProNAi Therapeutics, Inc. is a privately held biopharmaceutical company. In April 2014, ProNAi Therapeutics raised $59.5 Million in a Series D Financing.

ProNAi’s institutional investors include:

  • Vivo Capital, Palo Alto, CA
  • Frazier Healthcare Ventures, Menlo Park, CA
  • OrbiMed Advisors, New York, NY
  • Adams Street Partners, Chicago, IL
  • RA Capital Management, Boston, MA
  • Caxton Alternative Management, New York, NY
  • Hopen Life Science Ventures, Grand Rapids, MI
  • Sectoral Asset Management, Montreal, QC
  • Janus Capital Management, Denver, CO
  • Apjohn Ventures, Kalamazoo, MI
  • Grand Angels, Grand Rapids, MI
  • Michigan Strategic Fund/MEDC
  • Biosciences Research Commercialization Center, Kalamazoo, MI
  • Sigvion Ventures, Chicago, IL
  • Amherst Fund, Ann Arbor, MI
  • BlueWater Angels, Midland, MI